ClinicalTrials.gg
Active, not recruitingNCT04527380Updated Aug 12, 2026Results posted

A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

A Phase 3 interventional study of Ixekizumab and Adalimumab in Juvenile Psoriatic Arthritis and Enthesitis Related Arthritis, sponsored by Eli Lilly and Company. Active, not recruiting at 43 sites in 12 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-08-12.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
101
Allocation
Randomized
Ages
2 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 53 studies in Arthritis, Juvenile with a site in Germany — 14 open to participants now, 17 under way, 11 of them phase 3. Arthritis, Juvenile · Germany.

Enrollment
20th of 45
101 · median 86
Started
2021
with 1 other
Phase 3
32 of 53
10 open now
Primary completion
2024-02
later than 0 of 16 live
Registered
38th of 53
by date
Lead sponsor
3 of 53
Eli Lilly and Company

Among the 53 studies in Arthritis, Juvenile with a site in Germany, this one is the 20th largest by enrollment of the 45 interventional ones that give a count, is one of 2 that started in 2021, is one of 32 in phase 3, reaches primary completion later than 0 of the 16 other live ones, and was the 38th registered.

Arthritis, Juvenile

366 studies on the registry are indexed under Arthritis, Juvenile; 102 are open to participants now.

Browse Arthritis, Juvenile studies →

Open to participants now

14 of the 53 studies in Arthritis, Juvenile with a site in Germany are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 69 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 50 (72%) stop at 75 or younger; 65 take children under 18; 11 take healthy volunteers.

This study: 2 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Arthritis, Juvenile with a site in Germany, or all of them as a file.
02

Study summary

The reason for this study is to see if the study drug ixekizumab is safe and effective in children with juvenile idiopathic arthritis (JIA) categories of enthesitis-related arthritis (ERA) (including juvenile onset ankylosing spondylitis [JoAS]) and juvenile psoriatic arthritis (JPsA).

03

Conditions studied

  • Juvenile Psoriatic Arthritis
  • Enthesitis Related Arthritis

Browse trials for

04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have active juvenile idiopathic arthritis (categories of enthesitis related arthritis or juvenile psoriatic arthritis)
  • Participants must have weight of at least 10 kilograms (Kg), age starting at 2 years for participants with juvenile psoriatic arthritis and starting at 6 years for participants with enthesitis related arthritis
  • Participants must have all immunizations up-to-date in agreement with current immunization guidelines, in the opinion of the investigator

Exclusion criteria

Exclusion Criteria:

  • Participants must not have active or history of inflammatory bowel disease
  • Participants must not have active uveitis
  • Participants must not have active or latent tuberculosis
  • Participants must not have an active infection
  • Participants must not have concurrent use of biologic agents for the treatment of the juvenile idiopathic arthritis
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
101 participants (actual)

Study arms

  • Experimental
    Ixekizumab - OLT Period

    Participants received subcutaneous (SC) ixekizumab from week 0 to week 16, following dosing regimens based on body weight: * Greater than (\>) 50.0 kg: Starting dose 160 mg at week 0, then 80 mg SC every 4 weeks (Q4W) from week 2 to week 16. * 25.0-50.0 kg: Starting dose 80 mg at week 0, then 40 mg SC Q4W from week 2 to week 16. * 10.0 to less than (\<) 25.0 kg: Starting dose 40 mg at week 0, then 20 mg SC Q4W from week 2 to week 16.

    Drug: Ixekizumab

  • Active comparator
    Adalimumab - OLT Period

    Participants received SC adalimumab from week 0 to week 16, following dosing regimens based on body weight: * Greater than or equal to (≥) 30.0 kg: 40 mg SC every 2 weeks (Q2W). * 10.0 to \<30.0 kg: 20 mg SC Q2W.

    Drug: Adalimumab

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 30 (Ixekizumab - OLT Period)

    JIA ACR, is comprised of 6 variables: number of active joints, number of joints with limited range of motion, Physician's Global Assessment of Disease Activity, Parent's Global Assessment of Well-Being, physical function (measured by the Childhood Health Assessment Questionnaire \[CHAQ\]), and acute-phase reactants (high-sensitivity C-reactive protein \[hsCRP\] and erythrocyte sedimentation rate \[ESR\]). A JIA ACR30 response is defined as at least 30% improvement from baseline in at least 3 of any 6 variables in the core set, with no more than 1 of the remaining variables worsening by more than 30%.

    Time frame: Week 16

Secondary outcomes

  1. Percentage of Participants Achieving JIA ACR 30 (Adalimumab - OLT Period)

    JIA ACR, is comprised of 6 variables: number of active joints, number of joints with limited range of motion, Physician's Global Assessment of Disease Activity, Parent's Global Assessment of Well-Being, physical function (measured by the Childhood Health Assessment Questionnaire \[CHAQ\]), and acute-phase reactants (high-sensitivity C-reactive protein \[hsCRP\] and erythrocyte sedimentation rate \[ESR\]). A JIA ACR30 response is defined as at least 30% improvement from baseline in at least 3 of any 6 variables in the core set, with no more than 1 of the remaining variables worsening by more than 30%.

    Time frame: Week 16

  2. Percentage of Participants Achieving JIA ACR 50/70/90/100 (OLT Period)

    JIA ACR, is comprised of 6 core set variables: number of active joints, number of joints with limited range of motion, Physician's Global Assessment of Disease Activity, Parent's Global Assessment of Well-Being, physical function (measured by the Childhood Health Assessment Questionnaire \[CHAQ\]), and acute-phase reactants (high-sensitivity C-reactive protein \[hsCRP\] and erythrocyte sedimentation rate \[ESR\]). A JIA ACR 50/70/90 response is defined as a greater than or equal to (≥) 50/70/90/100% improvement from baseline in at least 3 of any 6 variables in the core set, with no more than 1 of the remaining variables worsening by more than 30%.

    Time frame: Week 16

  3. Percentage of Participants Achieving JIA ACR 30/50/70/90/100 (OLE Period)

    JIA ACR, is comprised of 6 core set variables: number of active joints, number of joints with limited range of motion, Physician's Global Assessment of Disease Activity, Parent's Global Assessment of Well-Being, physical function (measured by the Childhood Health Assessment Questionnaire \[CHAQ\]), and acute-phase reactants (high-sensitivity C-reactive protein \[hsCRP\] and erythrocyte sedimentation rate \[ESR\]). A JIA ACR 30/50/70/90 response is defined as a greater than or equal to (≥) 30/50/70/90/100% improvement from baseline in at least 3 of any 6 variables in the core set, with no more than 1 of the remaining variables worsening by more than 30%.

    Time frame: Week 104

  4. Change From Baseline in Psoriasis Area and Severity Index (PASI) for Juvenile Psoriatic Arthritis (JPsA) Participants With at Least 3% Body Surface Area (BSA) at Baseline (OLT Period)

    The PASI is an index that combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling (S), redness (R), and plaque induration/infiltration thickness (T) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Severity is rated for each index (R, S, T) on a 0 to 4 scale (0 for no involvement up to 4 for severe involvement): 0 = none 1. = slight 2. = moderate 3. = severe 4. = very severe The various body regions are weighted to reflect their respective proportion of BSA.

    Time frame: Baseline, Week 16

  5. Change From Baseline in Psoriasis Area and Severity Index (PASI) for Juvenile Psoriatic Arthritis (JPsA) Participants With at Least 3% Body Surface Area (BSA) at Baseline (OLE Period)

    The PASI is an index that combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling (S), redness (R), and plaque induration/infiltration thickness (T) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Severity is rated for each index (R, S, T) on a 0 to 4 scale (0 for no involvement up to 4 for severe involvement): 0 = none 1. = slight 2. = moderate 3. = severe 4. = very severe The various body regions are weighted to reflect their respective proportion of BSA.

    Time frame: Baseline, Week 104

  6. Change From Baseline in Leeds Enthesitis Index (LEI) for Participants With Enthesitis Related Arthritis (ERA) at Baseline (OLT Period)

    The LEI was developed specifically for use in psoriatic arthritis (PsA). It measures enthesitis at 6 sites (lateral epicondyle of humerus, right/left (R/L); medial femoral condyle, (R/L); Achilles tendon insertion, (R/L)). Each site is assigned a score of 0 (absent) or 1 (present); the results from each site are then added to produce a total score (range 0 to 6) with the higher scores indicating more severe enthesitis.

    Time frame: Baseline, Week 16

  7. Change From Baseline in Leeds Enthesitis Index (LEI) for Participants With Enthesitis Related Arthritis (ERA) at Baseline (OLE Period)

    The LEI was developed specifically for use in psoriatic arthritis (PsA). It measures enthesitis at 6 sites (lateral epicondyle of humerus, right/left (R/L); medial femoral condyle, (R/L); Achilles tendon insertion, (R/L)). Each site is assigned a score of 0 (absent) or 1 (present); the results from each site are then added to produce a total score (range 0 to 6) with the higher scores indicating more severe enthesitis.

    Time frame: Baseline, Week 104

  8. Percentage of Participants With Disease Flare (OLT Period)

    Disease flare is defined as worsening of ≥30% from baseline in at least 3 of the 6 JIA ACR core set criteria and an improvement of ≥30% in no more than one of the criteria. The JIA ACR, is comprised of 6 core set variables: number of active joints, number of joints with limited range of motion, Physician's Global Assessment of Disease Activity, Parent's Global Assessment of Well-Being, physical function (measured by the Childhood Health Assessment Questionnaire \[CHAQ\]), and acute-phase reactants (high-sensitivity C-reactive protein \[hsCRP\] and erythrocyte sedimentation rate \[ESR\]).

    Time frame: Week 2 through Week 16

  9. Percentage of Participants With Disease Flare (OLE Period)

    Disease flare is defined as worsening of ≥30% from baseline in at least 3 of the 6 JIA ACR core set criteria and an improvement of ≥30% in no more than one of the criteria. The JIA ACR, is comprised of 6 core set variables: number of active joints, number of joints with limited range of motion, Physician's Global Assessment of Disease Activity, Parent's Global Assessment of Well-Being, physical function (measured by the Childhood Health Assessment Questionnaire \[CHAQ\]), and acute-phase reactants (high-sensitivity C-reactive protein \[hsCRP\] and erythrocyte sedimentation rate \[ESR\]).

    Time frame: Baseline through Week 104

  10. Pharmacokinetics (PK): Trough Concentrations (C-trough) of Ixekizumab (Ixekizumab - OLT Period)

    C-trough were measured at specified time points to assess the minimum concentration of ixekizumab in the blood before the next dose was administered.

    Time frame: Week 4, 12 and 16 : Pre-dose

  11. Pharmacokinetics (PK): Trough Concentrations (C-trough) of Ixekizumab (Ixekizumab - OLE Period)

    C-trough were measured at specified time points to assess the minimum concentration of ixekizumab in the blood before the next dose was administered.

    Time frame: Week 20, 32, 56, 80 and 104 : Pre-dose

  12. Percentage of Participants With Treatment-emergent Positive Anti-ixekizumab Antibodies (Ixekizumab - OLT Period)

    Percentage of participants with treatment-emergent positive anti-ixekizumab antibodies was summarized by treatment group. Percentage was calculated based on the number of evaluable participants and was calculated by number of participants with treatment-emergent positive anti-ixekizumab antibodies / number of evaluable participants \* 100%.

    Time frame: Baseline through Week 16

  13. Percentage of Participants With Treatment-emergent Positive Anti-ixekizumab Antibodies (Ixekizumab - OLE Period)

    Percentage of participants with treatment-emergent positive anti-ixekizumab antibodies was summarized by treatment group. Percentage was calculated based on the number of evaluable participants and was calculated by number of participants with treatment-emergent positive anti-ixekizumab antibodies / number of evaluable participants \* 100%.

    Time frame: Baseline through Week 104

07

Results

Posted Jun 5, 2025

Participant flow

The results reported are for the primary outcome up to Week 16 (OLT period); data beyond Week 16 will be reported after study completion, at the time of final results reporting.

Participant flow — Overall Study
MilestoneIxekizumab - OLT PeriodAdalimumab - OLT Period
Started8120
Received at least one dose of study drug8120
Completed8019
Not completed11
Withdrew: Lack of efficacy01
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryPercentage of Participants Achieving Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 30 (Ixekizumab - OLT Period)

JIA ACR, is comprised of 6 variables: number of active joints, number of joints with limited range of motion, Physician's Global Assessment of Disease Activity, Parent's Global Assessment of Well-Being, physical function (measured by the Childhood Health Assessment Questionnaire \[CHAQ\]), and acute-phase reactants (high-sensitivity C-reactive protein \[hsCRP\] and erythrocyte sedimentation rate \[ESR\]). A JIA ACR30 response is defined as at least 30% improvement from baseline in at least 3 of any 6 variables in the core set, with no more than 1 of the remaining variables worsening by more than 30%.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 30 (Ixekizumab - OLT Period)
Percentage of participantsIxekizumab - OLT Period
Percentage of Participants Achieving Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 30 (Ixekizumab - OLT Period)88.9
SecondaryPercentage of Participants Achieving JIA ACR 30 (Adalimumab - OLT Period)

JIA ACR, is comprised of 6 variables: number of active joints, number of joints with limited range of motion, Physician's Global Assessment of Disease Activity, Parent's Global Assessment of Well-Being, physical function (measured by the Childhood Health Assessment Questionnaire \[CHAQ\]), and acute-phase reactants (high-sensitivity C-reactive protein \[hsCRP\] and erythrocyte sedimentation rate \[ESR\]). A JIA ACR30 response is defined as at least 30% improvement from baseline in at least 3 of any 6 variables in the core set, with no more than 1 of the remaining variables worsening by more than 30%.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving JIA ACR 30 (Adalimumab - OLT Period)
Percentage of participantsAdalimumab - OLT Period
Percentage of Participants Achieving JIA ACR 30 (Adalimumab - OLT Period)95.0
SecondaryPercentage of Participants Achieving JIA ACR 50/70/90/100 (OLT Period)

JIA ACR, is comprised of 6 core set variables: number of active joints, number of joints with limited range of motion, Physician's Global Assessment of Disease Activity, Parent's Global Assessment of Well-Being, physical function (measured by the Childhood Health Assessment Questionnaire \[CHAQ\]), and acute-phase reactants (high-sensitivity C-reactive protein \[hsCRP\] and erythrocyte sedimentation rate \[ESR\]). A JIA ACR 50/70/90 response is defined as a greater than or equal to (≥) 50/70/90/100% improvement from baseline in at least 3 of any 6 variables in the core set, with no more than 1 of the remaining variables worsening by more than 30%.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving JIA ACR 50/70/90/100 (OLT Period)
Percentage of participantsIxekizumab - OLT PeriodAdalimumab - OLT Period
ACR50 response7990.0
ACR70 response64.265.0
ACR90 response29.640.0
ACR100 response18.535.0
SecondaryPercentage of Participants Achieving JIA ACR 30/50/70/90/100 (OLE Period)

JIA ACR, is comprised of 6 core set variables: number of active joints, number of joints with limited range of motion, Physician's Global Assessment of Disease Activity, Parent's Global Assessment of Well-Being, physical function (measured by the Childhood Health Assessment Questionnaire \[CHAQ\]), and acute-phase reactants (high-sensitivity C-reactive protein \[hsCRP\] and erythrocyte sedimentation rate \[ESR\]). A JIA ACR 30/50/70/90 response is defined as a greater than or equal to (≥) 30/50/70/90/100% improvement from baseline in at least 3 of any 6 variables in the core set, with no more than 1 of the remaining variables worsening by more than 30%.

Time frame:
Week 104

Results for this outcome have not been posted.

SecondaryChange From Baseline in Psoriasis Area and Severity Index (PASI) for Juvenile Psoriatic Arthritis (JPsA) Participants With at Least 3% Body Surface Area (BSA) at Baseline (OLT Period)

The PASI is an index that combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling (S), redness (R), and plaque induration/infiltration thickness (T) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Severity is rated for each index (R, S, T) on a 0 to 4 scale (0 for no involvement up to 4 for severe involvement): 0 = none 1. = slight 2. = moderate 3. = severe 4. = very severe The various body regions are weighted to reflect their respective proportion of BSA.

Time frame:
Baseline, Week 16
Reported as:
Mean · score on a scale
Change From Baseline in Psoriasis Area and Severity Index (PASI) for Juvenile Psoriatic Arthritis (JPsA) Participants With at Least 3% Body Surface Area (BSA) at Baseline (OLT Period)
score on a scaleIxekizumab - OLT PeriodAdalimumab - OLT Period
Change From Baseline in Psoriasis Area and Severity Index (PASI) for Juvenile Psoriatic Arthritis (JPsA) Participants With at Least 3% Body Surface Area (BSA) at Baseline (OLT Period)-3.80 ± 3.541-0.70 ± NA
SecondaryChange From Baseline in Psoriasis Area and Severity Index (PASI) for Juvenile Psoriatic Arthritis (JPsA) Participants With at Least 3% Body Surface Area (BSA) at Baseline (OLE Period)

The PASI is an index that combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling (S), redness (R), and plaque induration/infiltration thickness (T) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Severity is rated for each index (R, S, T) on a 0 to 4 scale (0 for no involvement up to 4 for severe involvement): 0 = none 1. = slight 2. = moderate 3. = severe 4. = very severe The various body regions are weighted to reflect their respective proportion of BSA.

Time frame:
Baseline, Week 104

Results for this outcome have not been posted.

SecondaryChange From Baseline in Leeds Enthesitis Index (LEI) for Participants With Enthesitis Related Arthritis (ERA) at Baseline (OLT Period)

The LEI was developed specifically for use in psoriatic arthritis (PsA). It measures enthesitis at 6 sites (lateral epicondyle of humerus, right/left (R/L); medial femoral condyle, (R/L); Achilles tendon insertion, (R/L)). Each site is assigned a score of 0 (absent) or 1 (present); the results from each site are then added to produce a total score (range 0 to 6) with the higher scores indicating more severe enthesitis.

Time frame:
Baseline, Week 16
Reported as:
Mean · score on a scale
Change From Baseline in Leeds Enthesitis Index (LEI) for Participants With Enthesitis Related Arthritis (ERA) at Baseline (OLT Period)
score on a scaleIxekizumab - OLT PeriodAdalimumab - OLT Period
Change From Baseline in Leeds Enthesitis Index (LEI) for Participants With Enthesitis Related Arthritis (ERA) at Baseline (OLT Period)-1.63 ± 1.005-1.50 ± 0.577
SecondaryChange From Baseline in Leeds Enthesitis Index (LEI) for Participants With Enthesitis Related Arthritis (ERA) at Baseline (OLE Period)

The LEI was developed specifically for use in psoriatic arthritis (PsA). It measures enthesitis at 6 sites (lateral epicondyle of humerus, right/left (R/L); medial femoral condyle, (R/L); Achilles tendon insertion, (R/L)). Each site is assigned a score of 0 (absent) or 1 (present); the results from each site are then added to produce a total score (range 0 to 6) with the higher scores indicating more severe enthesitis.

Time frame:
Baseline, Week 104

Results for this outcome have not been posted.

SecondaryPercentage of Participants With Disease Flare (OLT Period)

Disease flare is defined as worsening of ≥30% from baseline in at least 3 of the 6 JIA ACR core set criteria and an improvement of ≥30% in no more than one of the criteria. The JIA ACR, is comprised of 6 core set variables: number of active joints, number of joints with limited range of motion, Physician's Global Assessment of Disease Activity, Parent's Global Assessment of Well-Being, physical function (measured by the Childhood Health Assessment Questionnaire \[CHAQ\]), and acute-phase reactants (high-sensitivity C-reactive protein \[hsCRP\] and erythrocyte sedimentation rate \[ESR\]).

Time frame:
Week 2 through Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants With Disease Flare (OLT Period)
Percentage of participantsIxekizumab - OLT PeriodAdalimumab - OLT Period
Percentage of Participants With Disease Flare (OLT Period)00
SecondaryPercentage of Participants With Disease Flare (OLE Period)

Disease flare is defined as worsening of ≥30% from baseline in at least 3 of the 6 JIA ACR core set criteria and an improvement of ≥30% in no more than one of the criteria. The JIA ACR, is comprised of 6 core set variables: number of active joints, number of joints with limited range of motion, Physician's Global Assessment of Disease Activity, Parent's Global Assessment of Well-Being, physical function (measured by the Childhood Health Assessment Questionnaire \[CHAQ\]), and acute-phase reactants (high-sensitivity C-reactive protein \[hsCRP\] and erythrocyte sedimentation rate \[ESR\]).

Time frame:
Baseline through Week 104

Results for this outcome have not been posted.

SecondaryPharmacokinetics (PK): Trough Concentrations (C-trough) of Ixekizumab (Ixekizumab - OLT Period)

C-trough were measured at specified time points to assess the minimum concentration of ixekizumab in the blood before the next dose was administered.

Time frame:
Week 4, 12 and 16 : Pre-dose
Reported as:
Geometric mean · micrograms per milliliter (µg/mL)
Pharmacokinetics (PK): Trough Concentrations (C-trough) of Ixekizumab (Ixekizumab - OLT Period)
micrograms per milliliter (µg/mL)Ixekizumab - OLT Period (>50 kg Group)Ixekizumab - OLT Period (25 to 50 kg Group)Ixekizumab - OLT Period (10 to <25 kg Group)
Week 44.43 ± 715.09 ± 383.28 ± 56
Week 123.25 ± 683.39 ± 572.95 ± 41
Week 163.47 ± 553.32 ± 372.80 ± 46
SecondaryPharmacokinetics (PK): Trough Concentrations (C-trough) of Ixekizumab (Ixekizumab - OLE Period)

C-trough were measured at specified time points to assess the minimum concentration of ixekizumab in the blood before the next dose was administered.

Time frame:
Week 20, 32, 56, 80 and 104 : Pre-dose

Results for this outcome have not been posted.

SecondaryPercentage of Participants With Treatment-emergent Positive Anti-ixekizumab Antibodies (Ixekizumab - OLT Period)

Percentage of participants with treatment-emergent positive anti-ixekizumab antibodies was summarized by treatment group. Percentage was calculated based on the number of evaluable participants and was calculated by number of participants with treatment-emergent positive anti-ixekizumab antibodies / number of evaluable participants \* 100%.

Time frame:
Baseline through Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants With Treatment-emergent Positive Anti-ixekizumab Antibodies (Ixekizumab - OLT Period)
Percentage of participantsIxekizumab - OLT Period
Percentage of Participants With Treatment-emergent Positive Anti-ixekizumab Antibodies (Ixekizumab - OLT Period)8.8
SecondaryPercentage of Participants With Treatment-emergent Positive Anti-ixekizumab Antibodies (Ixekizumab - OLE Period)

Percentage of participants with treatment-emergent positive anti-ixekizumab antibodies was summarized by treatment group. Percentage was calculated based on the number of evaluable participants and was calculated by number of participants with treatment-emergent positive anti-ixekizumab antibodies / number of evaluable participants \* 100%.

Time frame:
Baseline through Week 104

Results for this outcome have not been posted.

Adverse events

Collected over Baseline up to week 16 (until OLT period). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ixekizumab - OLT Period0/81 (0%)3/81 (3.7%)66/81 (81.5%)
Adalimumab - OLT Period0/20 (0%)3/20 (15%)15/20 (75%)
Most frequent serious events
Most frequent serious events
EventIxekizumab - OLT PeriodAdalimumab - OLT Period
BicytopeniaBlood and lymphatic system disorders0/811/20
Middle ear effusionEar and labyrinth disorders0/811/20
HypertransaminasaemiaHepatobiliary disorders0/811/20
Anaphylactic reactionImmune system disorders0/811/20
CellulitisInfections and infestations0/811/20
AsthmaRespiratory, thoracic and mediastinal disorders0/811/20
Acute sinusitisInfections and infestations1/810/20
TonsillitisInfections and infestations1/810/20
Acetabulum fractureInjury, poisoning and procedural complications1/810/20
Most frequent other events
Showing 10 of 165
Most frequent other events
EventIxekizumab - OLT PeriodAdalimumab - OLT Period
NasopharyngitisInfections and infestations11/814/20
Injection site reactionGeneral disorders13/811/20
HeadacheNervous system disorders13/812/20
NauseaGastrointestinal disorders2/812/20
Blood cholesterol increasedInvestigations0/812/20
Oropharyngeal painRespiratory, thoracic and mediastinal disorders8/812/20
Injection site painGeneral disorders8/810/20
VomitingGastrointestinal disorders7/810/20
Covid-19Infections and infestations7/810/20
Upper respiratory tract infectionInfections and infestations7/810/20

Baseline characteristics

As pre-specified in the statistical analysis plan, all randomized participants were reported, per treatment regimen, as exposure was the same across the different treatment groups.

Age, Continuous
Age, Continuous(years)Ixekizumab - OLT PeriodAdalimumab - OLT PeriodTotal
Mean13.10 ± 3.0713.30 ± 3.1613.10 ± 3.08
Sex: Female, Male
Sex: Female, Male(Participants)Ixekizumab - OLT PeriodAdalimumab - OLT PeriodTotal
Female36844
Male451257
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ixekizumab - OLT PeriodAdalimumab - OLT PeriodTotal
Hispanic or Latino26430
Not Hispanic or Latino26531
Unknown or Not Reported291140
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ixekizumab - OLT PeriodAdalimumab - OLT PeriodTotal
American Indian or Alaska Native11415
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American011
White691584
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Ixekizumab - OLT PeriodAdalimumab - OLT PeriodTotal
Argentina819
Belgium213
Czechia303
France303
Germany211031
Italy707
Mexico17421
Netherlands101
Spain505
Switzerland112
United Kingdom13316
08

Study locations

43 sites
09

References and documents

Publications

  • Ramanan AV, Ruperto N, Foeldvari I, Vega-Cornejo G, Keller S, Wang R, Araujo J, Sen P, Marulkar K, Tseng J, Pitou C, Quartier P. Ixekizumab in children with active psoriatic and enthesitis-related juvenile idiopathic arthritis (COSPIRIT-JIA): a multicentre, open-label, 16-week, Bayesian trial including a randomised reference group to adalimumab. Lancet Rheumatol. 2026 May;8(5):e377-e388. doi: 10.1016/S2665-9913(25)00346-7. Epub 2026 Mar 2. PubMed 41785908 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2021 to primary completion in Feb 2024, 34 months.

Results were first posted in Jun 2025, 1 year 3 months after primary completion.

Of 36 phase 3 interventional studies under Arthritis, Juvenile, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 70. This study's 34 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2020
First posted
Aug 26, 2020
StartActual
Apr 13, 2021
Primary completionActual
Feb 19, 2024
CompletionEst.
Jan 2029
Results first posted
Jun 5, 2025
Last update
Aug 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04527380
Responsible party
Sponsor
First posted
Aug 26, 2020
Start date
Apr 13, 2021
Primary completion
Feb 19, 2024
Completion
Jan 2029 (estimated)
Results posted
Jun 5, 2025
Last update
Aug 12, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM -5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ixekizumab

Start the discussion